Featured Image

Editor’s note (January 24, 2022): Subsections added include “What about the numbers of doses per batch?” and “Pfizer report of specific batch sizes reaffirms ‘total criminality.’” 

(LifeSiteNews) — A recent analysis of public government data reveals very high percentages of adverse events reported as a result of COVID-19 experimental “vaccine” injections, including over 21,000 deaths, have occurred in a small minority of product batches released by pharmaceutical manufacturers.

Furthermore, according to analysts, the wide dispersement of these highly toxic batches (or “lots”) to numerous U.S. states, along with their apparent sequential labeling according to levels of toxicity, is evidence of intentionality in  adulterating the contents of the shots and is thus likely a serious violation of federal regulations that require such products to have consistency.

In mid-November, London-based researcher Craig Paardekooper produced a short video drawing data from the  Vaccine Adverse Event Reporting System (VAERS) in the United States, where he discovered that “1 in 200 of the [COVID-19 vaccine] batches are highly toxic,” while the vast majority of them are not, at least according to short-term outcomes.

“In fact,” he continued, “70% of the batches for the vaccine-only produce one adverse reaction report in total,” and “80% of the vaccine batches only produce one or two adverse reaction reports.”

However, Paardekooper began to find anomalies that “produced thousands of times the number of adverse reactions” standing out from the vast majority of batches, including examples of 1,394, 1,012, and eventually to as many as 4,911 adverse reactions.

Additionally, these batches consistently produced these injuries across the many states where they were distributed, affirming the cause was the vaccine contents in the batches themselves rather than local circumstances, applications or demographics.

For example, for Pfizer, only 4% of their lots accounted for all the death reports associated with those injections and for Moderna the same was true with respect to only 5% of their batches.

In addition, unlike the more benign batches that were sent to fewer regional areas, the highly toxic injections were widely disseminated across multiple states.

As Paardekooper reported with regard to the Pfizer injections, only 2.9% of their lots were distributed to more than 12 states and these were associated with 96.5% of all the product’s deaths, 95.5% of all hospitalizations and 94.7% of all adverse event reports.

In significant contrast, 97.1% of the Pfizer lots were distributed to fewer than 12 states and were associated with only 3.5% of all product death reports, 4.5% of all hospitalizations, and 5.3% of all adverse event reports.

Given that this data is public, Paardekooper made an accompanying tutorial video explaining how anyone can replicate his findings by downloading and properly organizing the relevant data from the VAERS platform. He also set up a website called, which allows users to search the record of the adverse events of particular batches as is recorded in the VAERS data.

‘Highly unusual pattern’ indicates a ‘significant crime’ and ‘must be investigated’

Independent of these efforts, however, retired pharmaceutical industry executive Alexandra Latypova made her own query into this question and later, after connecting with Paardekooper, assembled a team of researchers with experience in clinical trials, data analysis, statistics, pharmaceutical industry regulations, manufacturing, and research and development to further analyze these figures.

She produced a 20-minute video highlighting the contrast between the tremendous variability of COVID-19 gene-transfer vaccine lots as compared with seasonal flu vaccines and stressed the importance of Good Manufacturing Practice (GMP) laws that she told LifeSiteNews are “designed to ensure safety and consistency of pharmaceutical products which must be produced in large quantities to very exacting standards of purity, stability, consistency, etc.”

“Breaches of these practices have historically resulted in tragic cases of adulterated, tainted, or poisoned drug products which resulted in loss of life and severe injuries,” she wrote in an email correspondence.

According to her presentation, GMP laws include expectations that every new lot/batch is “almost the same” as all previous lots, and that vaccines from different manufacturers “for a disease indication are ‘the same’ or interchangeable product.”

Quoting the specific regulation, Latypova said, “‘The failure to comply (with these practices) … shall render such drug to be adulterated,’ and that is a pretty significant crime to sell adulterated products.”

Establishing over 10 years of flu vaccine data as a control group in a visual graph (below), she demonstrated that in terms of the numbers of serious adverse events (SAEs), these products are very consistent, showing only two outliers with a maximum of 37 SAEs in one such lot.

Graphing the data from COVID-19 vaccines in the same way, she observed that the range of the SAEs had to be much higher, from 1 to 700 instead of from 1 to 40 with the flu shots to accommodate the enormous numbers of injuries associated with these injections.

Second, she pointed out how the lots from the three different companies “look completely different from each other,” and “lot to lot, they look extremely different as well” with many lots having very few SAEs and others having hundreds.

By comparison, she observed how “the flu vaccine outliers (the maximum number was 37) reside below the red line” and are clearly contrasted by the enormous spikes from the COVID vaccine “outlier” lots which are not just a few, but very numerous.

“This highly unusual pattern points to severe non-compliance in manufacturing and must be investigated,” Latypova concluded in a follow-up video.

What about numbers of doses per batch? Can that impact variability? 

When asked about the missing factor of batch size and how this might help explain the wide variability of adverse reactions between batches, the former pharmaceutical executive said, “We have a very good idea of the batch sizes.” 

Of course, if the batches showing thousands of adverse event reports are much larger than the 80% indicating only 1 or 2 adverse events, this could explain the wide variability in the VAERS data. 

But Latypova affirmed, “the batch sizes for these injection products are approximately 1.5 million doses.”  

In demonstration she shared a “Quality rolling review” document which was submitted by Pfizer to the European Medicines Agency on November 30, 2020, wherein the pharmaceutical giant specifically revealed “The target drug product batch size is 139 L (approximately 309,000 vials).” At 5 doses per vial, this confirms approximately 1.5 million doses per batch. 

And since this document was submitted just a couple of weeks prior to Pfizer beginning to ship these batches commercially, “this is clearly their target batch size,” Latypova affirmed. 

In further corroboration, she mentioned that her team has documentation from the CDC affirming 440 batch numbers from the three different products released in the United States (Pfizer, Moderna, & Janssen) with 349 of these appearing in VAERS chronologically.  

Multiplying these batch numbers by 1.5M doses each, we arrive at an approximate range of 660M doses delivered (440 x 1.5M), and around 523.5M used (349 x 1.5M) with the U.S. currently reporting almost 534M injections administered reasonably fitting into this range. 

Furthermore, “the average [number of doses administered] is smaller than the manufactured lot size because there are small differences in yield in manufacturing, and the ‘usage’ per lot is not 100%,” she added. And thus, “these calculations roughly correspond to what we know about the manufacturing lot sizes.” 

Pfizer report of specific batch sizes further indicates ‘total criminality’ 

Latypova, who worked for 20 years co-founding and managing companies which served the fields of clinical trials, data collection and analysis, shared another public document which Pfizer submitted to the FDA revealing significant data on 33 specific batches of their product, including their respective sizes. 

This “Response to Queries” from the regulatory agency shows early batches produced between July and October 2020 (p. 23-25, Table 13), which are smaller than normal (19,000 to 141,000 vials), all produced by a company called Polymun, which Latypova explains is “a pilot manufacturing facility” that develops the process for composition of the drug prior to the production being transferred to high scale manufacturing. 

“The early batches were probably produced for clinical trials,” she said, and those for which we have no data in VAERS “probably went to overseas clinical trial sites.” 

Regarding those batches for which there are respective adverse event reports in the VAERS system, Latypova said, “Notice that the rate of AEs per batch does not depend on the size! The small batches have similar AE rate as some of the large ones.” 

LifeSiteNews accessed the data from nine of the 33 batches for the purpose of illustration below and verified that, for example, despite batch EJ1686 having 98,280 fewer vials for distribution, it still had a comparable AE rate with EL1283 and only four fewer reported deaths (46 vs. 50). 

Date / 2020  Batch #  Vials  AEs  Disabilities  Deaths 
25 Sept.  EJ0553  164,580  2  0  0 
5 Oct.  EJ1685  159,315  1,720  35  42 
7 Oct.  EJ1686  147,615  1,443  17  46 
12 Oct.  EK4175  145,275  1  0  0 
16 Oct.  EK1768  141,960  5  0  0 
4 Nov.  EK9231  230,685  3,412  51  48 
3 Nov.  EL0739  294,239  2  0  0 
11 Nov.  EL1283  245,895  2,249  36  50 
12 Nov.  EJ6795  282,645  1  0  0 

She also noted the great variability between batches. Standing out we see how the EJ0553 (25 Sept) has more than 5,000 more vials than EJ1685 (5 Oct), yet the later batch has 860x the AEs including 42 deaths and 35 disabilities.  

The same dynamic is present in noticing how EL1283 (11 Nov.) has 1,124x the AEs as EL0739 which was produced 8 days earlier reaffirming the conclusions of these analysts that GMP laws have likely been violated.  

What this evidence indicates, “is total criminality in my opinion,” Latypova concluded. 

Batches labeled according to toxicity further indicating intentionality of variability

Another important observation Paardekooper documents includes what appears to be consistent patterns of labeling for ranges of toxicity in batches.

For example, he shows that Pfizer batches labeled with an alphanumeric code beginning in “EN6” are the most toxic with a range of 2,000 to 3,000 reported adverse reactions per batch, the “ER87 series” has between 1,500 and 2,500, the EW series has 1,000 to 2,000, and the “F series” is at 100 to 1,500 times base toxicity.

Paardekooper defines “base toxicity” to be one adverse reaction per batch, which is the case for 70% of all reported batches.

He explains the great concern here is this pattern of labeling “would be exactly what scientists would do if they were testing different dosages of drugs and monitoring their effects.”

Moderna has the same pattern wherein, for example, their batches ending with 20A or 21A are associated with very high levels of injury, with those ending in 20A being the most toxic. In fact, all of the batches producing more than 1,719 adverse events all end with the 20A label.

Further, the level of toxicity seems to correlate in descending and ascending order as indicated by letters in the center of the batch numbers, with the higher toxicity rating containing the letters J, K, L, M, and the less A, B, C, D, E, and F.

As illustrated by one Telegram post on the topic, the unexpected and early death of one 48-year-old surgeon was highlighted in the New York Post last May with the deceased displaying a picture of his vaccine card showing two injections from “20A” Moderna shots received earlier in the year.

As the more toxic batches have been dispersed widely across the United States, one incident from California suggests one of them may not have been distributed broadly enough to escape notice. In January 2021, state health officials halted the distribution of “Moderna Lot 041L20A” due to “a higher-than-usual number of possible allergic reactions” at one vaccination site.

This pause was intended to allow investigation by the manufacturer, the FDA and CDC, yet it was lifted only a few days later when it was announced such bodies “found no scientific basis to continue the pause,” granting providers permission to “immediately resume” the injections.

According to data from, as of December 29, 2021, “Moderna Lot 041L20A” shots charted 2,679 VAERS reports of adverse reactions, including 32 deaths, 29 individuals with life threatening illnesses, and 26 with disabilities.

As should always be remembered, VAERS is a passive reporting system that has historically“under-reported adverse events by about two orders-of-magnitude” as is verified by a Harvard Pilgrim study that found “fewer than 1%” of adverse effects from vaccines are reported to VAERS. Even vaccine manufacturers have calculated a likely “fifty-fold underreporting of adverse events” in this system. Therefore, the actual injuries from these batches may be 10 to 100 times higher than reported.

‘We are now absolutely certain it is not the same stuff in every vial’ and ‘criminal acts are being committed’

Presenting much of this material in a January 7 comprehensive interview with German international trial attorney Reiner Fuellmich and his associates of the German Corona Investigative Committee, Dr. Michael Yeadon, former Pfizer vice president and chief scientist for allergy & respiratory, offered commentary drawing from 32 years in the pharmaceutical industry leading new medicines research.

Addressing the enormous variability of the batches, he said, “We are now absolutely certain it is not the same stuff in every vial. And that means criminal acts are being committed.”

“It’s not just the extreme toxicity, but it’s the variability,” he said. “That means it’s not the same products. … it’s not the same stuff. I am certain. It’s not an assessment. It’s not a ‘maybe.’ I’m absolutely certain [this is the case].”

Having worked with Latypova on this project, presenting the same graphs that can be viewed above, he said, “It cannot be the case that these middle Pfizer lots are the same material as the ones immediately to the left and to the right.”

“These drug companies are highly professional outfits. They know how to manufacture reproducibly, and we saw that with the flu vaccines over decades. They know how to do it, [and yet] they haven’t done it.

“I’m afraid I’ve come to the conclusion that they’re doing it on purpose because … after a year they know this data,” he said. “They can go into VAERS … and see what’s happening. They know. So, the fact that they haven’t stopped this tells me that they are at least okay with it, and I fear that this is deliberate.”

Commenting on the fact that the most toxic batches were distributed broadly across the nation to many states, while the less dangerous ones were sent to fewer localities, Yeadon observed, “If this was innocent, then you would expect that a batch (or a lot) would go on average to the same number of states each time.”

“And we need to go and check this but certainly as of a couple of weeks ago our findings were the most toxic batches were going to the largest number of states. And if that’s confirmed, again [this would be] evidence of premeditation. How would they know ahead of time to distribute, to dilute, the most toxic batches across the largest number of states?”

Dr. Wolfgang Wodarg, a former head of the health committee of the Parliamentary Assembly of the Council of Europe, and a panel member for this interview, concluded, “[this is] a big crime. And it’s so obvious.”

“We have to wake up the doctors and wake up the pharmacists and wake up the people that they are just victims of criminals,” he said.

‘This is intentional, premeditated, mass murder,’ ‘crimes against humanity’

Coming from a legal perspective, Fuellmich responded to the evidence stating, “At this point in time, I think this must be considered the missing link. This is the smoking gun.”

According to the international attorney whose professional record includes litigating against fraudulent corporations, the evidence is “enough to show us that what has been happening is that within this gigantic experiment they are experimenting with lethal dosages.”

“[And] for what purpose?” he asked. “It can only be [that] they want to reduce the population without us understanding this. That’s why they’re experimenting with lethal dosages because if they killed everyone at the first shot it would be very obvious,” he said.

“[This evidence is] way more than enough for me,” the attorney continued. “And [it] should be way more than enough for any prosecutor.”

“I have no doubt, that if we talk to all of the experts that we have spoken to, the psychologists, the psychiatrists, the epidemiologists, the immunologists, the lawyers, the economists, they will all come to the same conclusion: This is intentional, premeditated, mass murder. There’s absolutely no doubt about it because nothing else makes any sense,” he said.

“These are crimes against humanity,” Fuellmich concluded. “We’re going to get them.”


COVID shots intended to reduce world’s population by poisoning ‘billions’: South African doctor
Brief video illustrates dramatic spikes in COVID-19 deaths after jabs in 40 nations
Ontario doctor resigns over forced vaccines, says 80% of ER patients with mysterious issues had both shots
It’s ‘entirely possible’ vaccine campaigns ‘will be used for massive-scale depopulation’: Former Pfizer VP
EXCLUSIVE – Former Pfizer VP: ‘Your government is lying to you in a way that could lead to your death.’